Press coverage about Regeneron Pharmaceuticals (NASDAQ:REGN) has trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.2264429278102 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Cancer Space Update: Roche, Pfizer & Regeneron Make Data Presentations (finance.yahoo.com)
- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts’ Recommendations to Consider – Nasdaq Journal (press release) (nasdaqjournal.com)
- Cramer’s lightning round: Buy Regeneron, it’s not getting the credit it deserves (finance.yahoo.com)
- Cramer's lightning round: Buy Regeneron, it's not getting… (finance.yahoo.com)
- Regeneron (REGN) & Sanofi (SNY) Report Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab (streetinsider.com)
Regeneron Pharmaceuticals (NASDAQ REGN) traded up $5.83 during trading hours on Friday, reaching $388.95. The company’s stock had a trading volume of 1,271,116 shares, compared to its average volume of 903,586. Regeneron Pharmaceuticals has a 52 week low of $340.09 and a 52 week high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The stock has a market cap of $41,543.44, a price-to-earnings ratio of 33.48, a P/E/G ratio of 1.52 and a beta of 1.53.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. During the same period in the previous year, the business earned $3.13 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. analysts anticipate that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current year.
A number of equities analysts have weighed in on REGN shares. Canaccord Genuity reiterated a “buy” rating and set a $522.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Credit Suisse Group reiterated a “buy” rating and set a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Citigroup reiterated a “buy” rating and set a $575.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 7th. UBS reduced their price objective on Regeneron Pharmaceuticals from $535.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, September 21st. Finally, Guggenheim reiterated a “buy” rating and set a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $465.40.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,500 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Charles A. Baker sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $450.00, for a total value of $900,000.00. Following the sale, the director now owns 11,000 shares of the company’s stock, valued at $4,950,000. The disclosure for this sale can be found here. 10.80% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Regeneron Pharmaceuticals (REGN) Stock Price” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.thelincolnianonline.com/2017/12/15/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-regeneron-pharmaceuticals-regn-stock-price.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.